Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
Date:4/28/2011

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in Paris, France.

"The data we are accumulating for carfilzomib continues to support its potential as an important new treatment option for patients with multiple myeloma.  Data from several studies will be presented at the upcoming IMW meeting, including interim data in newly diagnosed patients from a Multiple Myeloma Research Consortium study being led by Dr. Andrzej Jakubowiak at the University of Michigan Comprehensive Cancer Center that is evaluating carfilzomib in combination with a standard therapy," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Onyx is committed to bringing this promising therapy to patients as quickly as possible and remains on track for filing a new drug application with the U.S. Food and Drug Administration as early as mid-year under the accelerated approval process.  We are also actively enrolling patients in the Phase 3 FOCUS trial for the treatment of patients with relapsed and refractory myeloma to support a filing with the European Medicines Agency, as well as, in the Phase 3 ASPIRE trial in relapsed multiple myeloma."

Carfilzomib data highlights include:

Carfilzomib and other new proteasome inhibitors: Clinical data

  • Andrzej Jakubowiak, M.D., Ph.D., University of Michigan Comprehensive Cancer Center, USA
  • Thursday, May 5, 2011, 14:19 – 14:31
  • Oral Session Name: Plenary Session I: New Drugs and Therapeutic Approaches

Results of PX-171
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
2. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
7. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
10. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
11. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oct. 31, 2014  Lycera Corp., a biopharmaceutical ... autoimmune disease and cancer, today announced that data ... agonist product candidates will be presented at the ... Cancer (SITC) being held November 6-9, 2014 at ... Harbor, MD.  The poster, entitled " Novel synthetic ...
(Date:10/31/2014)... , Oct. 31, 2014 ThynkWare ( www.thynkware.com ... patients initiate text and email messages using their thoughts. ... technology invented by ThynkWare,s founder, Duane Cash , ... smartphone device. This technology allows users to control their ... power of thought. ThynkWare provides the interface ...
(Date:10/31/2014)... LAVAL, QC , Oct. 31, 2014 /CNW Telbec/ ... is poised, with its strategic plan, for accelerated growth ... 2014 was 32.6% and revenues reached $17,862,341. Net income ... $3 million threshold for the first time in the ... this growth, the Company joined the forces of its ...
Breaking Medicine Technology:Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5
... CHICAGO and NEW YORK, Dec. 6, 2010 With as ... developing Alzheimer,s,(1) the Alzheimer,s Association and Pfizer (NYSE: ... disease by emphasizing to all Americans, "It,s Time to Face ... related to their personal experience with the disease in an ...
... Following the annual meeting of its stockholders on Friday, ... ) announced that its stockholders approved the reappointment of ... C. Wallen as directors of the Company.  In addition, ... PricewaterhouseCoopers LLP as its independent registered public accounting firm. ...
Cached Medicine Technology:National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's' 2National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's' 3National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's' 4Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm 2Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm 3
(Date:10/31/2014)... to life. The last stage, when two daughter cells ... dawn of cell biology in the Victorian era. For ... study this final step, when the dividing cell creates ... given to this process by those early biologists, cytokinesis, ... a highly active and organized series of events. Scientists ...
(Date:10/31/2014)... — A team from the Broad Institute, the ... California, Santa Cruz, was awarded one of three ... contracts with the goal of building a system ... Genome Atlas (TCGA) and other datasets by co-locating ... one cloud environment. This co-location will enable researchers ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Energy Textiles ... gear. The new gear is now available online, and ... the benefits of Celliant infrared-active athletic gear over compression ... that another contract has been signed for Under Armour ... for the next eight years. In light of this ...
(Date:10/31/2014)... treatment and cost, patients with early stage breast ... (APBI) with proton therapy versus whole breast irradiation ... of Texas MD Anderson Proton Therapy Center. ... on typical patient characteristics, researchers used Medicare reimbursement ... types of partial and whole breast irradiation therapies ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
... America,s pharmaceutical research companies are testing 109 medicines and ... to a report released today by the Pharmaceutical Research and ... anniversary of "World AIDS Day" - a global awareness campaign ... Health on Programmes for AIDS Prevention. , ...
... allows patients to control their own pain medication, but a new ... Commission Journal on Quality and Patient Safety shows that errors ... in patient harm than errors that occur with other medications. ... than 9,500 PCA errors over a five-year period in the United ...
... for HIV Prevention, Calls on Governments to Increase Investment in ... (Para tener acceso a una copia completa de la declaracion ... , WASHINGTON, Dec. 1 An ... Latina women in the United States is demanding increased access ...
... ARCADIS family of products highlights the cutting-edge of intraoperative imaging ... Siemens Healthcare ( ... family of next-generation ARCADIS(R) C-Arm systems, featuring outstanding image quality, ... 94th Scientific Assembly and Annual Meeting of the Radiological Society ...
... independent study at the,University of Cumbria found that nine in every ... exercising. The games reduce the boredom of,exercise. , ... to use exercise equipment,combined with video games provided by a company ... could play their games only while they maintained movement on,the fitness ...
... Appear in Upcoming TV Commercial - , , ... Whitening Expressions is "FanTaste-ic!" Crest Whitening Expressions and flavor expert ... contest in search of a new catch phrase that best ... "FanTaste-ic" was selected from over 600 contest entries, and America voted ...
Cached Medicine News:Health News:109 Medicines and Vaccines Now in Development for HIV/AIDS 2Health News:109 Medicines and Vaccines Now in Development for HIV/AIDS 3Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 2Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 3Health News:Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom 2Health News:Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom 3Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 3Health News:Children Tell Researchers: We'll Get Fit if It's Fun 2Health News:Video: America Votes Crest Whitening Expressions Is FanTaste-ic! 2
... Immunoassay (EIA) IgG & IgM Test System is ... presumptive detection of human IgG & IgM antibodies ... system should be used to test serum from ... with B. burgdorferi. All positive and equivocal specimens ...
... TheraTears in a bottle becomes preservative-free ... turns into oxygen and water on ... eyes with mild to moderate dryness ... maintenance treatment. Now you can have ...
... sutures are prepared by coating the ... caprolactone/glycolide copolymer and calcium stearoyl lactylate. ... increase visibility and are also available ... established by the United States Pharmacopeia ...
... QualiCode™ B. burgdorferi IgG/IgM Western Blot Kits ... detection of antibodies to Borrelia burgdorferi. Proteins ... disruption. Purified B. burgdorferi antigens are fractionated ... a polyacrylamide slab gel in the presence ...
Medicine Products: